CurrentCapital BluecrossPolicy AHS - G2063 - Testing for Diagnosis of Active or Latent Tuberculosis

Testing for Diagnosis of Active or Latent Tuberculosis

This policy defines coverage criteria and limitations for laboratory and molecular tests used to diagnose active tuberculosis (TB) and to screen for latent TB infection (LTBI) for Capital Bluecross members.

Policy Summary

PayerCapital Bluecross

PolicyTesting for Diagnosis of Active or Latent Tuberculosis

Policy CodePolicy AHS - G2063 - Testing for Diagnosis of Active or Latent Tuberculosis

Change TypeNo material change

Effective DateSep 18, 2015

Next Review DateApr 1, 2026

Key ActionObtain and document appropriate microbiologic specimens (at least two sputum specimens for pulmonary TB) and request rapid molecular testing and cultures when TB is suspected.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Specificity >95%IGRA specificity (LTBI)

Sensitivity 80-90%IGRA sensitivity (LTBI)

Sensitivity 96% / Specificity 99%NAAT performance

Sens 67.9% / Spec 97.6%Urine LAM (CD4<100)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Culture = gold standard

Coverage criteria for TB testing

Denial Risk

Provider impact / Denial triggers

Prior authorization: Not specified in the provided excerpt.

Complete medical evaluation recommended by CDC prior to diagnosing active TB (medical history, physical exam, test for TB infection, chest radiograph, bacteriologic examination including smear, NAAT, culture, and DST).
Government/public health guidance and laboratory standards take precedence for reporting, confirmatory testing, and management (CDC, WHO, NIH, ATS/CDC/ERS/IDSA, local/state health departments).
Denial triggers — tests explicitly NOT meeting coverage criteria in this policy: quantitative NAATs for Mycobacterium spp., whole genome sequencing for detection of drug resistance, genotyping, ADA and IFN-γ fluid assays for extrapulmonary TB diagnosis, and serum biomarker/panel tests.
No specific authorization or denial process is specified in the excerpt; check member benefits and applicable state/federal regulations for any prior authorization requirements.
When ordering testing for suspected active TB, ensure documentation of clinical signs/symptoms, radiographic findings, and specimen source; follow guideline-recommended testing algorithms to avoid non-covered or low-utility tests.

IGRA for LTBI

IGRA for latent TB infection (LTBI) — Covered when ALL of the following are met for LTBI screening:

ALL of the following

Individual is at risk for Mtb infection or testing is required by law/credentialing.
Test is being performed for latent TB infection (LTBI) screening, not to diagnose active TB.
Provider has performed or will perform clinical evaluation to exclude active TB disease (CDC five-component evaluation when indicated).

Diagnostic testing for active TB

Diagnostic testing for active TB — Covered tests for suspected active TB:

ALL of the following

AFB smear/stain on appropriate specimens.
Mycobacterial culture and species identification in a quality-assured laboratory.
Qualitative NAAT (eg, Xpert MTB/RIF, Xpert Ultra, Truenat) on initial respiratory or other appropriate specimens when TB is suspected.

Molecular DST indications

Molecular-based drug susceptibility testing — coverage when one of following criteria met:

ANY of the following

Individual has been treated for TB in the past.
Individual was born in or has lived ≥1 year in a foreign country with moderate or high TB incidence or high MDR prevalence.
Individual is a contact of a person with MDR-TB.
Individual is HIV infected.

Repeat DST

Repeat drug susceptibility testing — Repeat phenotypic DST coverage (any of):

ANY of the following

Sputum cultures remain positive after 3 months of treatment (or per guideline-specified timeframes such as 4 months).
Bacteriological reversion from negative to positive at any time.

Additional covered indications

Additional covered indications — Other covered testing situations:

ANY of the following

Fluid cell counts and chemistries for suspected extrapulmonary TB.
Urine LF-LAM for HIV-positive patients with CD4 ≤100 cells/µL and signs/symptoms of TB (or per WHO criteria for inpatient/advanced disease).
NAAT on extrapulmonary specimens when indicated (eg, CSF for TB meningitis).

Not covered / Experimental tests

Not covered / experimental tests — Tests explicitly not covered:

ANY of the following

Quantitative NAATs for mycobacteria.
Whole genome sequencing for drug resistance detection.
Genotyping of Mycobacterium spp.
ADA and IFN-γ fluid assays for extrapulmonary TB diagnosis.
Serum biomarker panels for TB.
Commercial serodiagnostic serology tests (excluded per WHO).

Guideline-based coverage contexts

Guideline-based coverage contexts — Recommendations and contexts where testing is recommended per CDC/WHO/NIH/ATS/IDSA/ERS/NICE/USPSTF/AAP/NTCA:

ALL of the following

Select tests and specimens according to established guideline indications (WHO/CDC/NIH/ATS/ERS/IDSA/NICE/USPSTF/AAP/NTCA).
Ensure clinical evaluation and documentation to distinguish LTBI from active disease prior to LTBI treatment.
Use rapid molecular tests for initial diagnosis where indicated; perform culture and DST as complementary tests.

Applicable procedure and related coding

Applicable CPT/HCPCS procedure codesmixed

No codes listed

Applicable CPT/HCPCS Procedure Codesmixed

81099	Unlisted urinalysis procedure.
82945	Glucose, body fluid, other than blood.
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified.
83615	Lactate dehydrogenase (LD), (LDH);
84157	Protein, total, except by refractometry; other source (e.g., synovial fluid, cerebrospinal fluid).
84311	Spectrophotometry, analyte not elsewhere specified.
87070	Culture, bacterial; any other source except urine, blood, or stool, aerobic, with isolation and presumptive identification of isolates.
87077	Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate.
87116	Culture, tubercle, or other acid-fast bacilli (e.g., TB, AFB, mycobacteria) any source, with isolation and presumptive identification of isolates.
87150	Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.

1–10 of 27

1/3

Mantoux (TST) Induration Threshold

Mantoux (TST) induration threshold>= 5 mm for certain immunocompromised adults (interpretation per NICE: induration of 5 mm or larger regardless of BCG history)

Context for 5 mm thresholdApplied when assessing immunocompromised adults (e.g., HIV with low CD4, post-transplant) per NICE guidance

Action when positiveIf Mantoux ≥5 mm and active TB is excluded, consider IGRA or evaluate for LTBI treatment per clinical guidelines

Provider responsibilities, documentation, and authorization notes

Prior Authorization

Prior authorization note — covered IGRAs and molecular/culture tests

Interferon gamma release assays (IGRAs) and the molecular and culture-based tests listed in the policy meet coverage criteria when used according to the policy indications for LTBI screening and for diagnosis of suspected TB.

IGRA meets coverage criteria for LTBI screening in at-risk individuals or when screening is required by law.
AFB smear/stain, culture and culture-based DST, and qualitative NAAT meet coverage criteria for suspected TB.

Prior Authorization

Prior authorization not specified — guidance emphasizes culture and NAAT/Xpert

The document does not specify payer-level prior authorization procedures in the referenced sections; guidance emphasizes use of culture and NAAT/Xpert as initial diagnostic tests per WHO/CDC recommendations rather than stating prior authorization requirements.

WHO recommends Xpert MTB/RIF or Xpert Ultra as initial diagnostic tests in many clinical contexts.
CDC recommends a complete medical evaluation including bacteriologic testing (smear, NAAT, culture, DST).

Background and scope

Mycobacterium tuberculosis infection spans from asymptomatic latent infection to active pulmonary or extrapulmonary disease. Culture isolation of M. tuberculosis remains the reference standard (gold standard) for diagnosis and provides isolates for species identification and phenotypic drug susceptibility testing; microbiologic diagnosis should include AFB smear and mycobacterial culture with reporting to public health authorities.

Definitions and key terms

IGRA — Interferon Gamma Release Assay

DefinitionInterferon gamma release assay (IGRA): blood tests measuring T‑cell release of interferon‑gamma (IFN‑γ) in response to Mycobacterium tuberculosis antigens, used to detect latent TB infection.

Intended usePrimarily used for screening for latent TB infection (LTBI), not to diagnose active TB disease.

Clinical considerationsPreferred over TST in individuals ≥5 years in many settings (e.g., prior BCG vaccination or unlikely to return for TST reading) per ATS/IDSA/CDC guidance.

NAAT — Nucleic Acid Amplification Test

DefinitionNucleic acid amplification test (NAAT): molecular assays (e.g., Xpert MTB/RIF, Xpert Ultra, MTD) for rapid detection of Mycobacterium tuberculosis complex DNA and selected resistance markers.

Use case

Policy Summary

PayerCapital Bluecross

PolicyTesting for Diagnosis of Active or Latent Tuberculosis

Policy CodePolicy AHS - G2063 - Testing for Diagnosis of Active or Latent Tuberculosis

Change TypeNo material change

Effective DateSep 18, 2015

Next Review DateApr 1, 2026

Key ActionObtain and document appropriate microbiologic specimens (at least two sputum specimens for pulmonary TB) and request rapid molecular testing and cultures when TB is suspected.

SourceLink

On This Page

Prior Authorization

Prior authorization not specified — rapid molecular and phenotypic DST guidance

No explicit payer prior authorization rules are stated in these clinical guidance excerpts; they describe clinical use of rapid molecular DST and phenotypic testing but do not impose prior authorization requirements.

NIH recommends phenotypic DST to first‑line drugs and repeat testing when cultures remain positive.
ATS/CDC/ERS/IDSA recommend rapid molecular DST for rifampin (with or without isoniazid) in specified risk groups.

Prior Authorization

Prior authorization — proprietary/novel test codes may need payer verification

Certain proprietary or novel tests are listed with specific codes (example: 0574U NanoDetect‑TB™); verification of payer‑specific prior authorization procedures may be required before submission.

0574U — Mycobacterium tuberculosis CFP‑10 LC‑MS (NanoDetect‑TB™) is listed as a proprietary test in the code table and may require payer verification.

Prior Authorization

Prior authorization — none specified in reference entries

The policy reference entries do not specify any general prior authorization requirements for the tests covered in the document.

No prior authorization requirements are listed in the cited reference entries.

Step Therapy

Diagnostic sequencing — perform smear and culture; NAAT is adjunctive

Diagnostic sequencing expects AFB smear and culture as core components; NAAT is adjunctive and does not replace smear and culture while culture is pending.

AFB smear/stain, mycobacterial culture, and molecular testing are integral to diagnosis; NAAT does not replace smear and culture in the diagnostic algorithm.
Culture remains the reference (gold standard) and provides isolates for identification and DST.

Step Therapy

No step therapy mandates specified — WHO recommends Xpert as initial test

WHO recommends Xpert MTB/RIF or Xpert Ultra as initial tests in many clinical contexts, but the policy does not mandate step‑therapy sequencing or require trials of other tests before Xpert.

Xpert/Xpert Ultra may be used as initial diagnostic tests in adults and children with signs/symptoms of pulmonary TB.
The document does not describe step‑therapy or mandated sequencing of tests.

Step Therapy

Step therapy not addressed — focus on DST and repeat testing when indicated

The policy excerpts do not describe step therapy protocols; recommendations instead emphasize performing appropriate drug susceptibility testing and repeat testing when cultures remain positive or relapse occurs.

Repeat resistance testing is recommended if sputum cultures remain positive at or after four months or become positive after conversion.
No step therapy protocols are provided in these sections.

Step Therapy

Step therapy — not applicable; select appropriate TST/IGRA and use rapid tests per guidance

Clinical guidance addresses appropriate selection of TST versus IGRA and use of rapid molecular tests and culture but does not impose step‑therapy sequencing for diagnostic evaluation.

NICE and ERS/ECDC recommend selecting TST or IGRA based on age, immune status, and clinical context and obtaining at least two sputum specimens plus rapid testing.
No step therapy sequencing is described.

Documentation Required

Required laboratory documentation and reporting — culture identification and public health reporting

Microbiologic diagnosis should include AFB smear and mycobacterial culture; positive cultures must be identified per CLSI and ASM guidance and reported to public health authorities.

Isolates recovered should be identified according to Clinical and Laboratory Standards Institute and ASM guidance.
Positive cultures are reportable to public health authorities for confirmation and DST.

Documentation Required

Microbiology documentation and public health reporting — submit isolates and report positives

Documented microbiologic confirmation must include culture identification of M. tuberculosis and submission of isolates for confirmation and drug susceptibility testing, with reporting of positive cultures to public health authorities.

Submit culture isolates identified as M. tuberculosis for confirmation and DST per jurisdictional requirements.
Report positive cultures to public health authorities for oversight and case management.

Documentation Required

Document active TB exclusion and diagnostic testing before LTBI treatment

Before initiating treatment for latent TB infection, document exclusion of active TB by assessing symptoms and obtaining a chest radiograph; when performing diagnostic testing for suspected TB, document specimen types and results for AFB smear, NAAT, and culture.

Exclude active TB by symptom assessment and chest radiograph; if radiographic signs suggest active disease, obtain appropriate samples.
Record specimen types and results when ordering AFB smear, NAAT, and culture.

Documentation Required

Specimen and test documentation — minimum sputum specimens and site‑appropriate sampling

Obtain and submit appropriate microbiologic specimens: at least two sputum specimens for pulmonary TB and specimens from appropriate extrapulmonary sites; request rapid molecular tests when clinically indicated and document MDR‑TB risk factors when requesting rifampin resistance testing.

Submit at least two sputum specimens and one for rapid molecular testing for pulmonary TB.
Collect site‑appropriate specimens for extrapulmonary TB and request culture, species identification, and DST as indicated.
Document risk factors for MDR‑TB when requesting rapid rifampin resistance testing.

Denial Risk

Denial triggers — explicitly non‑covered tests (repeat)

Quantitative NAAT, whole genome sequencing, genotyping, ADA/IFNγ in fluids, and serum biomarker panels are explicitly listed as tests that do not meet coverage criteria and therefore are denial triggers if billed for coverage.

Quantitative nucleic acid testing for Mycobacterium spp. and M. tuberculosis does not meet coverage criteria.
Whole genome sequencing and genotyping for Mycobacterium spp. do not meet coverage criteria.
ADA and IFN‑γ testing in body fluids and serum biomarker panels do not meet coverage criteria.

Denial Risk

Denial risk — complete CDC evaluation required and should be documented

CDC recommends a complete medical evaluation for TB disease including medical history, physical exam, test for TB infection, chest radiograph, and bacteriologic examination; failure to perform and document these components may result in incomplete diagnostic documentation.

Ensure medical history, physical examination, TB infection testing (IGRA or TST), chest radiograph, and bacteriologic testing are performed and documented.
Culture is the gold standard and should be obtained as part of the bacteriologic examination.

Denial Risk

Denial risk — omission of recommended diagnostic tests for suspected pulmonary TB

Failure to perform recommended diagnostic tests—specifically NAAT on the initial respiratory specimen, AFB smear, and both liquid and solid cultures—when pulmonary TB is suspected may adversely affect management and could affect coverage determinations.

Perform NAAT on the initial respiratory specimen from patients suspected of pulmonary TB.
Perform AFB smear and both liquid and solid mycobacterial cultures on specimens as recommended.

Billing Rule

Billing/documentation risk — government coverage takes precedence

If this policy conflicts with applicable government coverage (e.g., LCDs, NCDs, or state Medicaid), the government policy controls; providers should follow the applicable government policy to avoid coverage denial.

Check relevant Local Coverage Determinations (LCDs), National Coverage Determinations (NCDs), and state Medicaid rules for precedence.
Use government guidance to resolve conflicts with this policy.

Recommended on initial respiratory specimens from patients suspected of pulmonary TB to provide rapid diagnostic information.

Specimen typesUsed on respiratory and selected extrapulmonary specimens (CSF, lymph node aspirate, stool, etc.) per WHO recommendations.

Culture Isolation of M. tuberculosis (Gold Standard)

DefinitionCulture isolation of Mycobacterium tuberculosis: growth of M. tuberculosis on solid or liquid media and identification per CLSI/ASM — the reference (gold) standard for microbiologic diagnosis of TB.

Performance notesLiquid culture methods are more sensitive (81.5–85.8%) and faster than solid media; combined use increases overall sensitivity.

Public health requirementPositive M. tuberculosis cultures should be submitted to public health authorities for confirmation and drug susceptibility testing.

NAA / Xpert — Rapid Detection Assays

DefinitionNAA / Xpert: Rapid nucleic acid amplification assays (e.g., Xpert MTB/RIF, Xpert Ultra) used for detection of M. tuberculosis complex and for rapid identification of rifampicin resistance.

Role in careWHO recommends Xpert/Xpert Ultra as initial tests for pulmonary (and many extrapulmonary) TB presentations to detect TB and rifampin resistance rapidly.

Specimen guidanceCan be applied to sputum, gastric aspirate, nasopharyngeal aspirate, stool, CSF and other site-appropriate specimens depending on clinical context.

LF-LAM — Lateral Flow Urine Lipoarabinomannan Assay

DefinitionLF-LAM: Lateral flow urine lipoarabinomannan assay — a point-of-care urine antigen test that detects mycobacterial LAM to assist diagnosis of active TB in selected HIV-positive patients.

Indicated populationWHO strongly recommends LF-LAM to assist diagnosis in hospitalized HIV-positive adults, adolescents and children who are symptomatic or seriously ill, and in some cases irrespective of symptoms when CD4 <200 cells/mm3.

Performance noteUrine LAM has high specificity and variable sensitivity (e.g., specificity ~97.6% and sensitivity ~67.9% in patients with CD4 <100), useful as an adjunct in high-risk HIV patients.

LTBI — Latent Tuberculosis Infection

DefinitionLatent TB infection (LTBI): Infection with M. tuberculosis in which organisms are alive but contained by the immune system; persons have no symptoms, are not infectious, and typically have a positive TST or IGRA.

Clinical implicationIndividuals with LTBI may be offered preventive therapy after active TB is excluded; testing strategy (IGRA vs TST) depends on age, BCG history, and risk factors.

Screening recommendationsUSPSTF recommends screening asymptomatic adults 18+ at increased risk for LTBI; IGRA often preferred in BCG-vaccinated persons and those unlikely to return for TST reading.

NAAT — (Respiratory and Extrapulmonary Specimens)

DefinitionNAAT (respiratory & extrapulmonary): Nucleic acid amplification tests used on primary respiratory and selected extrapulmonary specimens for rapid detection of M. tuberculosis complex and resistance markers.

RecommendationPerform NAAT on initial respiratory specimens for suspected pulmonary TB; WHO supports NAAT use for several extrapulmonary specimen types depending on presentation.

PurposeProvides rapid diagnostic information to guide infection control and treatment while culture is pending.

Mantoux (TST) — Positive Interpretation

Mantoux (TST) positive — definitionInduration of 5 mm or larger is considered positive in certain immunocompromised contexts (per NICE), regardless of prior BCG vaccination.

When to assessIf Mantoux ≥5 mm, assess for active TB; if active TB is excluded, consider IGRA for further evidence to decide on LTBI treatment per NICE guidance.

Pediatric noteNICE advises only to consider using IGRA alone in children and young people if Mantoux testing is not available or impractical.

Rapid Molecular Test

DefinitionRapid molecular test: NAAT performed on primary specimens (e.g., Xpert MTB/RIF, Xpert Ultra) to identify Mycobacterium tuberculosis complex and to detect rifampin resistance.

Clinical roleUsed as an initial diagnostic test in many settings to rapidly detect TB and rifampin resistance and to inform early treatment and public health actions.

Follow-upPositive rapid molecular results should be followed by culture and phenotypic DST as indicated to guide comprehensive drug susceptibility profiling.

Document Reference Set

Reference set overviewDocument references include guideline documents (WHO, ATS/IDSA/CDC, USPSTF, NICE, ERS/ECDC, AAP) and primary studies evaluating diagnostic assays (NAAT, LF-LAM, culture methods, proteomic and LC-MS approaches).

Assay evaluationsReferences cite diagnostic accuracy studies for NAAT (e.g., Bourgi et al.), urine LAM evaluations, GeneXpert performance, and culture method meta-analyses.

Methods and standardsReferences include CLSI/ASM laboratory manuals and evidence syntheses relevant to culture, identification, and DST methodologies.